본문 바로가기
KERD
논문KCI 등재

외상후 스트레스 장애 환자에서 Mirtazapine과 Sertraline의 치료효과 및 안정성

Efficacy and Tolerability of Mirtazapine and Sertraline in Treatment of Patients with Posttraumatic Stress Disorder with Depression : A Randomized Open Label Trial

김성수|전용주|김완철|전은미|민경호|정문용
대한신경정신의학회 (Korean Neuropsychiatric Association)|2005.03|신경정신의학 (JOURNAL OF THE KOREAN NEUROPSYCHIATRIC ASSOCIATION)|제44권 제2호|pp. 165-175

4

조회

0

다운로드

1

인용

0

참고문헌

주제분류정신과학

초록

Abstract

Objectives：The aim of this study was to investigate the potential use of mirtazapine in Korean veterans diagnosed with PTSD,by comparing it with sertraline, a drug approved for use in PTSD in the USA. Methods：Efficacy was eveluated by Clinician Adninistered PTSD Scale (CAPS-2), the Hamilton Rating Scale for Depressin(HAMD-17) and the Clinical Global lmpresaion Scale (CGI), at baseline and week 1, 2, 6. Response was defined as a ≥30% decrease in CAPS-2 total score, a ≥50% decrease in total HAMD-17 score, and s CGI-I score<3. Results：51 patients on mirtazapine (measn age/duration of illness：59.1/33.5 yrs) and 49 on sertratine (mean age/duration of illness：60.6/35.6 years) completed the study. Mean daily dosage was 34.1 mg for mirtazapine and 101.5 mg for sertraline. On CAPS-2 total score more patients responded in the mirtazapine group at weak 1 (13 vs. 2%) and week 2 (51vs. 31%). At week 6 this difference was statistically significant (88 vs. 69%, p=0.039), CAPS-2 total score. HAMD-17 total score and CGI-I score decreased significantly in both groups, with no significant differences between groups on all time points. Main side effects for the rnirtazapine group：dry mouth (19.8%) and constipation (19.6%), somnolence (15.7%), weight gain (1.96%). For the sertraline group：indigestion (14.3%), palpitation (6.1%) agitation (2.0%), epigastric soreness (2.0%), insomnia (2.0%),sexual dysfunction (2.0%). Conclusion：Mirtazapine appeared to be an effective and well-tolerated treatment for PTSD in Korean veterans.

참고문헌 (59)

  1. "참전 재향군인에서 외상 후 스트레스 장애의 유병상태와 관련요인 분석" (1996), 연세대학교 보건대학원
  2. "Current diagnostic issues and epidemiologicalinsights in PTSD", 3(2), pp.2 11~14 (1998)
  3. "Posttraumaticstress disorder in the national comorbidity survey", 52, pp.1048~1060 (1995)
  4. "Traumatic events andposttraumatic stress disorder in an urban population of young adults", 48, pp.216~222 (1991)
  5. "Prevalenceof civilian trauma and posttraumatic stress disorder in a representativenational sample of women", 61, pp.984~991 (1993)
  6. "Posttraumatic stress disorder in an urban populationof young adults:risk factors for chronicity", 149, pp.671~675
  7. "Cortisol alteration in PTSD. In: Yehuda R, Shier A, Mc-Farlane A, eds. International Handbook of Human Response to Trauma", pp.265~283 (2000)
  8. "The neurobiology of anxiety disorder. In:Charney DS, Nestler EJ, Bunny BS. Neurobiology of mental Illness.", pp.494~517 (1999), Oxpord University Press
  9. "A randomized clinical trial of phenelzineand imipramine for posttraumatic disorder", 145, pp.1289~1291
  10. "Treatment of posttaumatic disorderwith amitriptyline and placebo", 47, pp.259~266 (1990)
  11. "Pharmacotherapy for posttraumatic stress disorderusing phenelzine or imipramine", 179, pp.366~370 (1991)
  12. "A double-blind, placebo-controlled,multi center study of brofaromine in the treatment of posttraumaticstress disorder", 122, pp.386~389 (1995)
  13. "Core symptoms of posttraumaticstress disorder unimproved by alprazolam treatment", 51, pp.236~238
  14. "Treatment of recent trauma survivors withbenzodiazepines:a prospective study", 57, pp.390~394 (1996)
  15. "A preliminary study of lamotriginefor the treatment of posttraumatic stress disorder", 45, pp.1226~1229 (1999)
  16. "Fluoxetineversus placebo in posttraumatic stress disorder", 63, pp.199~206 (2002)
  17. "Fluvoxamine treatmentin veterans with combat-related post-traumatic stress disorder", 15, pp.29~33 (2002), Depression and Anxiety
  18. "An open-label,12-week clinicaland sleep EEG study of nefazodone in chronic combat-relatedposttraumtic stress disorder", 62, pp.789~796 (2001)
  19. "Open trial of nefazodone forcombat veterans with posttraumatic stress disorder", 14, pp.453~60 (2001)
  20. "Efficacy and safety of sertraline treatment of posttraumatic stressdisorder:a randomized controlled trial", 283, pp.1837~1844 (2000)
  21. "Characterizingthe effects of sertraline in post-traumatic stress disorder", 32, pp.661~670 (2002)
  22. "Double-blind placebo-controlled pilot study of sertraline in militaryveterans with posttraumatic stress disorder", 22, pp.190~195 (2002)
  23. "Efficacy and safetyof paroxetine treatment of chronic PTSD:a fixed-dose,placebo-controlledstudy", 158, pp.1982~1988 (2001)
  24. "Selective serotonin reuptake inhibitors:meta-analysisof discontinuation rates", 9, pp.47~53 (1994)
  25. "Selective serotonin reuptake inhibitors:metaanalysisof efficacy and acceptability", 306, pp.683~687 (1993)
  26. "The efficacy of selective serotonin reuptakeinhibitors in depression:a meta analysis of studies against tricyclicantidepressants", 8, pp.238~249 (1994)
  27. "The effects of mirtazapine on central noradrenergic andserotonergic neurotransmission", 10(4), pp.19~23 (1995)
  28. "A risk-benefit assessmentof mirtazapine in the treatment of depression", 17, pp.251~264 (1997)
  29. "Pharmacology of rapid-onset antidepressant treatment strategies", 62(15), pp.12~17 (2001)
  30. "The pharmacologic profile of mirtazapine", 57(4), pp.19~25
  31. "The clinical relevance of preclinical data:mirtazapine, a model compound", 17(1), pp.29~34 (1997)
  32. "Mirtazapine:a review of its pharmacology andtherapeutic potential in the management of depression", 5, pp.389~402 (1996)
  33. "Clinical efficacy of mirtazapine:a review of meta-analysisof pooled data", 10(4), pp.25~35 (1995)
  34. "A pilot study of mirtazapinein posttraumatic stress disorder", 14, pp.29~31 (1999)
  35. "Safety of mirtazpine:a review", 10, pp.37~45 (1995)
  36. "Paper presented at 26th annual Meeting of associationfor advancement of Behavior therapy"
  37. "임상가를 위한 외상후 스트레스 장애 척도의 신뢰도,타당도 연구", 38, pp.514~522 (1999)
  38. "Clinical evaluation of a measure to assess combat exposure.PsycholAssessment", 1, pp.53~55 (1989)
  39. "Mississippi scale for combatrelatedposttraumatic stress disorder:three studies in reliability andValidity", 56, pp.85~90 (1988)
  40. "A rating scale for depression", 23, pp.56~62
  41. "ECDEU assessment Manual for Psychopharmacology US Department of Health", pp.218~338 222 (1976)
  42. "Acute and long-term actions ofthe antidepressant drug mirtazapine on central 5-HT neurotransmission", 51, pp.255~266 (1998)
  43. "The alpha2-adrenoceptor antagonistOrg 3770 enhances serotonin transmission in vivo", 253, pp.~6 (1994)
  44. "The selective alpha2-adrenoceptor antagonistmirtazapine(Org 3770) enhances noradrenergic and 5-HT1A mediatedserotonergic neurotransmission", 4(1), pp.29~38 (1995)
  45. "The alpha2 selective adrenoceptorantagonist Org3770(mirtazapine, Remeron) enhances noradrenergicand serotonergic transmission", 10(2), pp.2~118 (1995)
  46. "The effects of mirtazapineon the interactions between central noradrenorgic and serotonergicsystems", 4(1), pp.13~17 (1995)
  47. "Effects of long-term treatmentwith the alpha2-adrenoceptor antagonist mirtazapine on 5-HT transmission", 355, pp.20~29 (1997)
  48. "Serotonergic studies in patients withaffective and personality disorders", 46, pp.587~599 (1989)
  49. "Psychobiologic predictors of suicide", 48(12), pp.39~43
  50. "5-HIAA in the cerebrospinal fluid:a biochemical suicide predictor", 33, pp.1193~1197 (1976)
  51. "Noradrenergic and serotonergic functionin posttraumatic stress disorder", 54, pp.749~758 (1997)
  52. "Pharmacology of antidepressants", 17(1), pp.2~18 (1997)
  53. "Current advance and trend in the treatment ofdepression", 15, pp.220~226 (1994)
  54. "Clinical pharmacokineticsof mirtazapine", 38, pp.461~474 (2000)
  55. "Influence of hepatic impairmenton the pharmacokinetics of single dose of mirtazapine in elderly subjects", 35, pp.76~ (1992)
  56. "Mirtazapine efficacy and tolerabilityin comparison with fluoxetine in patients with moderate to severemajor depressive disorder", 59, pp.306~312 (1998)
  57. "The use of mirtazapine in a patient with chronicpain", 18, pp.382~385 (1999)
  58. "Focus on mirtazapine", 31, pp.455~469 (1996)
  59. "Sertraline treatment of posttraumaticstress disorder:results of 24 weeks of open-label continuationtreatment", 62, pp.325~331 (2001)

관련 논문AI추천

A Comparison of Mirtazapine and Paroxetine for the Treatment of Patients with Posttraumatic Stress Disorder: A Randomized Open-label Trial박원명, 서호준, 전태연, 채정호, Young-Eun Jung대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2010 · 제8권 제2호우울증 환자 치료에 있어서 Tianeptine과 Sertraline의 효과와 안전성 비교이철, 강성민, 기백석, 백인호, 연병길, 오병훈, 이민수, 채정민대한신경정신의학회 · 신경정신의학2001 · 제40권 제2호주요우울증에 대한 Milnacipran의 효과 및 안전성 : Fluoxetine과의 비교이철, 기백석, 김정범, 백인호, 연병길, 오강섭, 오병훈, 이민수, 정한용, 지익성, 최병무, 함병주대한신경정신의학회 · 신경정신의학2004 · 제43권 제4호Comparison of Side Effect Profiles between Mirtazapine and Selective Serotonin ReuptakeInhibitors ; A Naturalistic SettingJeong-Ho Chae, Kwang-Soo Kim, Kyoung-Uk Lee, Tae-Youn Jun, Tae-Yul Lew, Won-Myong Bahk, Yoon-Kyung Shin대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2004 · 제2권 제1호Efficacy and Tolerability of Generic Mirtazapine (Mirtax) for Major Depressive Disorder: Multicenter, Open-label, Uncontrolled, Prospective Study김원, 권영준, 김문두, 민경준, 박원명, 서정석, 송후림, 신영철, 우영섭, 이상열, 정종현대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2015 · 제13권 제2호Sertraline의 약동학, 약력학 및 항우울효과에 관한 고찰최정옥대한생물치료정신의학회 · 생물치료정신의학1995 · 제1권 제1호

이 간행물의 다른 논문 (17건)

외상후 스트레스 장애의 치료정문용pp. 145-146외상후 스트레스 장애에 대한 안구운동 민감소실 및 재처리 요법김대호pp. 147-151외상후 스트레스 장애의 수면김린, 임세원pp. 152-157외상후 스트레스 장애의 경두개자기자극치료채정호, 송정민pp. 158-164정신과에서 심박 변이도(Heart Rate Variability)의 이용우종민, 채정호, 김원pp. 176-184
원문 보기